Starpharma Vállalati érték
Mi az Starpharma Vállalati érték?
A Vállalati érték az Starpharma Holdings Limited - $114.27M
Mi a Vállalati érték meghatározása?
A vállalati érték a vállalat teljes piaci értékének mértéke. A piaci kapitalizáció az adósság, a kisebbségi részesedés és a preferált részvények összege, a pénzeszközök és pénzeszköz-egyenértékek összege mínusz.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Vállalati érték a Health Care szektor a ASX-on cégekben a Starpharma -hoz képest
Mit csinál Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
vállalati érték -hoz hasonló cégek Starpharma
- Pure Gold Mining nak Vállalati érték $113.91M van
- Suoxinda nak Vállalati érték $114.05M van
- Amaroq Minerals Ltd nak Vállalati érték $114.10M van
- Dixie nak Vállalati érték $114.16M van
- smartphoto group NV nak Vállalati érték $114.18M van
- Ramco Systems nak Vállalati érték $114.25M van
- Starpharma nak Vállalati érték $114.27M van
- Alpha Real Trust nak Vállalati érték $114.32M van
- Sylogist nak Vállalati érték $114.35M van
- ScS Plc nak Vállalati érték $114.38M van
- Paragon ID SA nak Vállalati érték $114.38M van
- Probe Metals nak Vállalati érték $114.42M van
- Zoetic International Plc nak Vállalati érték $114.43M van